ES2124852T3 - Formulaciones de rapamicina para administracion oral. - Google Patents

Formulaciones de rapamicina para administracion oral.

Info

Publication number
ES2124852T3
ES2124852T3 ES94307117T ES94307117T ES2124852T3 ES 2124852 T3 ES2124852 T3 ES 2124852T3 ES 94307117 T ES94307117 T ES 94307117T ES 94307117 T ES94307117 T ES 94307117T ES 2124852 T3 ES2124852 T3 ES 2124852T3
Authority
ES
Spain
Prior art keywords
approximately
rapamicine
formulations
oral administration
volume
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES94307117T
Other languages
English (en)
Inventor
Robert Paul Waranis
Thomas Waymond Leonard
Maureen Murphy Harrison
Christian Luther Ofslager
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Wyeth LLC
Original Assignee
American Home Products Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by American Home Products Corp filed Critical American Home Products Corp
Application granted granted Critical
Publication of ES2124852T3 publication Critical patent/ES2124852T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1277—Preparation processes; Proliposomes

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

LA PRESENTE INVENCION SE REFIERE A NUEVAS FORMULACIONES DE RAPAMICINA ORALES QUE CONTIENEN DE 0,01 GRAMOS APROXIMADAMENTE A 10,00 GRAMOS APROXIMADAMENTE DE RAPAMICINA POR CADA 100 ML DE LA FORMULACION Y UN SISTEMA SOLVENTE QUE CONTIENE DE UN 0,1 APROXIMADAMENTE A UN 10% APROXIMADAMENTE EN VOLUMEN DE SURFACTANTE, DE UN 0 APROXIMADAMENTE A UN 25% APROXIMADAMENTE EN VOLUMEN DE SOLVENTE INERTE Y DE UN 65 APROXIMADAMENTE A UN 99,95% APROXIMADAMENTE EN VOLUMEN DE UNA SOLUCION DE LECITINA O FOSFOLIPIDA.
ES94307117T 1993-09-30 1994-09-29 Formulaciones de rapamicina para administracion oral. Expired - Lifetime ES2124852T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US12952993A 1993-09-30 1993-09-30
US12952393A 1993-09-30 1993-09-30

Publications (1)

Publication Number Publication Date
ES2124852T3 true ES2124852T3 (es) 1999-02-16

Family

ID=26827648

Family Applications (1)

Application Number Title Priority Date Filing Date
ES94307117T Expired - Lifetime ES2124852T3 (es) 1993-09-30 1994-09-29 Formulaciones de rapamicina para administracion oral.

Country Status (12)

Country Link
EP (1) EP0648494B1 (es)
AT (1) ATE173628T1 (es)
AU (1) AU688782B2 (es)
DE (2) DE69414810T2 (es)
DK (1) DK0648494T3 (es)
ES (1) ES2124852T3 (es)
FI (1) FI115033B (es)
GR (1) GR3029439T3 (es)
HU (1) HU220870B1 (es)
LU (1) LU90832I2 (es)
NL (1) NL300055I2 (es)
SG (1) SG47803A1 (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH686761A5 (de) 1993-05-27 1996-06-28 Sandoz Ag Galenische Formulierungen.
DE4336434A1 (de) * 1993-10-26 1995-04-27 Hoechst Ag Pharmazeutische Zubereitung für die parenterale, enterale und dermale Verabreichung von praktisch unlöslichen Arzneistoffen und Verfahren zu ihrer Herstellung
MY129435A (en) * 1994-10-26 2007-04-30 Novartis Ag Pharmaceutical microemulsion preconcentrates
FR2736550B1 (fr) 1995-07-14 1998-07-24 Sandoz Sa Composition pharmaceutique sous la forme d'une dispersion solide comprenant un macrolide et un vehicule
GB9601120D0 (en) * 1996-01-19 1996-03-20 Sandoz Ltd Organic compounds
GB2331924A (en) * 1997-12-08 1999-06-09 Phares Pharm Res Nv Lipid compositions and their use
CA2356959C (en) * 1998-12-22 2009-03-31 The United States Of America, Represented By The Secretary, Department Of Health And Human Services Water-insoluble drug delivery system
US6682758B1 (en) 1998-12-22 2004-01-27 The United States Of America As Represented By The Department Of Health And Human Services Water-insoluble drug delivery system
EP1478648B1 (en) 2002-02-01 2014-04-30 ARIAD Pharmaceuticals, Inc. Phosphorus-containing compounds and uses thereof
WO2005110360A2 (en) * 2004-05-18 2005-11-24 Phares Pharmaceutical Research N.V. Compositions for injection
KR101478164B1 (ko) * 2006-02-09 2014-12-31 산텐 세이야꾸 가부시키가이샤 안정한 제제와 그 제조 및 사용 방법
CN106061482A (zh) 2013-10-08 2016-10-26 拉姆医疗公司 用于治疗淋巴管平滑肌瘤病的雷帕霉素
RU2016136348A (ru) * 2014-02-11 2018-03-16 Лэм Терапьютикс, Инк. Рапамицин для лечения лимфангиолейомиоматоза
NZ724756A (en) 2014-04-04 2023-07-28 Ai Therapeutics Inc An inhalable rapamycin formulation for treating age-related conditions
CA2963085C (en) 2014-10-07 2023-02-21 Lam Therapeutics, Inc. An inhalable rapamycin formulation for the treatment of pulmonary hypertension

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU543727B2 (en) * 1980-06-02 1985-05-02 Ayerst Mckenna & Harrison Inc. Injectable composition of rapamycin
US5100899A (en) * 1989-06-06 1992-03-31 Roy Calne Methods of inhibiting transplant rejection in mammals using rapamycin and derivatives and prodrugs thereof
GB9103430D0 (en) * 1991-02-19 1991-04-03 Smithkline Beecham Plc Novel compound
IL111003A0 (en) * 1993-09-30 1994-11-28 American Home Prod Multi-component oral rapamycin formulation

Also Published As

Publication number Publication date
ATE173628T1 (de) 1998-12-15
HK1010342A1 (en) 1999-06-17
DE69414810D1 (de) 1999-01-07
FI944535A0 (fi) 1994-09-29
HU220870B1 (en) 2002-06-29
DK0648494T3 (da) 1999-08-09
SG47803A1 (en) 1998-04-17
EP0648494B1 (en) 1998-11-25
NL300055I1 (nl) 2001-12-01
FI115033B (fi) 2005-02-28
GR3029439T3 (en) 1999-05-28
EP0648494A1 (en) 1995-04-19
AU7420594A (en) 1995-04-13
LU90832I2 (fr) 2001-11-12
NL300055I2 (nl) 2002-04-02
HUT71115A (en) 1995-11-28
FI944535L (fi) 1995-03-31
HU9402786D0 (en) 1994-12-28
DE10199046I1 (de) 2002-01-10
AU688782B2 (en) 1998-03-19
DE69414810T2 (de) 1999-04-22

Similar Documents

Publication Publication Date Title
CO5011119A1 (es) Jarabe antihistaminico estabilizado
DK0948965T3 (da) Stabile medicinske præparater indeholdende 4,5-epoxymorphinanderivater
EP0221732A3 (en) Sustained release tablets
ES2169105T3 (es) Agentes antitromboticos tripeptidicos.
BR9912694A (pt) Composto para preparar medicamento de administração pulmonar
ATE163540T1 (de) Retinoid enthaltende, wässrige, gelartige darreichungsform
ES2076935T3 (es) Compuesto de pirazolopiridina y procedimientos para su preparacion.
PT1033981E (pt) Formulacoes e metodos para reduzir a toxicidade de agentes antineoplasicos
FR2784294B1 (fr) Composition cosmetique et/ou dermatologique renfermant au moins un extrait de murier, au moins un extrait de scutellaire et au moins un derive d'acide salicylique
PA8453201A1 (es) Formulaciones farmaceuticas que contienen voriconazol
ES534598A0 (es) Un procedimiento para preparar una solucion acuosa que contiene una sustancia farmaceutica soluble en lipidos
EP0222614A3 (en) Orally administerable sustained release pharmaceutical formulations
AR033688A1 (es) Composicion parenteral reconstituible
ES2169262T3 (es) Composiciones oftalmicas que contienen ciclodextrinas y compuestos de amonio cuaternario.
IT1314185B1 (it) Composizione farmaceutica per somministrazione di sostanze attivescarsamente solubili in mezzi acquosi
NL300055I2 (nl) Rapamycinepreparaten voor orale toediening.
ES2040363T3 (es) Procedimiento para la obtencion de derivados aromaticos.
ATE107853T1 (de) Orales, melatonin enthaltendes arzneimittel.
DK0656780T3 (da) Lægemidler, der indeholder diphosphonsyrer og salte deraf.
ES2033379T3 (es) Soluciones acuosas de clorhidrato de doxorubicina.
HUP0102075A2 (hu) Stabil mitoxantron-oldatok, eljárás az előállításukra
ES2106025T3 (es) Analogos de gangliosidos semisinteticos.
PT742716E (pt) Composicao farmaceutica para administracao transdermica sistemica contendo a substancia activa morfina-6-glucuronido
ES2129392T3 (es) Derivados de di-lisogangliosidos.
CO4970788A1 (es) Formulaciones orales para drogas hidrofilicas

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 648494

Country of ref document: ES

SPCF Request for supplementary protection certificate filed

Free format text: PRODUCT NAME: SIROLIMUS (RAPAMUNE), REGISTRY NO/DATE: EU/1/01/171/001-005 20010313, FIRST REGISTRY NO/DATE: CH55243. 01 20000926

Spc suppl protection certif: C200100027

Filing date: 20010912